P38 MAPK Is Involved In Epigenetic Regulation Of Fibrotic Genes In Replication Induced Senescence In Lung Fibroblasts

Aging Pathway
Therapeutic
A study found that a signaling pathway called p38 MAPK plays a role in how genes that cause scarring in the lungs are turned on in aging lung cells, suggesting that blocking this pathway could be a way to treat age-related lung scarring diseases.
Author

Gemini

Published

March 15, 2026

Our bodies have cells called fibroblasts that are crucial for repairing tissues after injury. However, sometimes these cells become overactive, leading to excessive scarring, a process known as fibrosis. In the lungs, this can result in a severe condition called idiopathic pulmonary fibrosis (IPF), where the lung tissue becomes stiff and scarred, making it difficult to breathe. This disease is often associated with aging.

Recent research has shed light on a key mechanism contributing to this harmful scarring. Scientists investigated how a specific signaling pathway, known as p38 MAPK, influences the activity of genes responsible for fibrosis in lung fibroblasts that are undergoing senescence, a state where cells stop dividing but remain metabolically active and can contribute to disease.

The study revealed that in aging lung fibroblasts, particularly those stimulated by a growth factor called TGF-β1, the p38 MAPK pathway becomes persistently active. This sustained activity leads to changes in how genes are expressed without altering the underlying DNA sequence itself—a process called epigenetic regulation. Specifically, the p38 MAPK pathway was found to promote a type of epigenetic modification called histone H4K16 acetylation, which essentially “turns on” fibrotic genes like α-SMA and Col3A1, leading to increased scarring.

Crucially, when researchers used drugs to block the p38 MAPK pathway, they observed a significant reduction in the expression of these scarring-related genes in both laboratory-grown lung fibroblasts and cells taken directly from IPF patients. This suggests that by inhibiting p38 MAPK, it might be possible to interrupt the harmful epigenetic changes that drive fibrosis.

These findings are significant because they point to a potential new therapeutic strategy for age-related fibrotic diseases like IPF. By targeting the p38 MAPK pathway, we might be able to prevent or reduce the excessive scarring that devastates lung function in these conditions.


Source: link to paper